OUR RESEARCH IS ABOUT YOU.

FORWARD is featured on “Health Uncensored with Dr. Drew.” on FOX Business, Sept. 22 @ 5:30pm ET.
As a participant, share your story with us using our user-friendly online questionnaires.
As a health care provider, expand your ability to help your patients by partnering with us.
Learn about our pioneering research efforts that have been ongoing for the past 30+ years.

Active Studies

FORWARD

FORWARD is the largest patient-reported research databank for rheumatic disorders in the United States. Started in 1999, our main registry is home to tens of thousands of participants spanning dozens of autoimmune conditions.

Lupus

The Lupus Study is part of the FORWARD Registry, has over 5,000 participants, and was started in 2002. This registry captures many of the different forms of lupus, including, but not limited to Systemic Lupus Erythematosus (SLE), Cutaneous Lupus, and Discoid Lupus.

Psoriasis/Psoriatic Arthritis

The Psoriasis Study is our newest and fastest-growing study made to help people who have psoriasis. It started in 2023 and its goal is to identify risk factors for the development of cardiovascular disease, diabetes, and psoriatic arthritis among patients with psoriasis. Visit the main Psoriasis Registry page to learn more.

Dupuytren

The Dupuytren Study is home to over 10,000+ participants with the sole purpose of finding a cure for Dupuytren’s Disease. This registry was started in 2020 with the Dupuytren Research Group, and together we use the data you give us to work to find and test medicines to fix the cause of Dupuytren disease and avoid procedures.

Spondyloarthritis

The Spondyloarthritis Databank is part of the FORWARD Registry, has over 4,000 participants, and was started in 2002. This registry captures many of the different forms of lupus, including, but not limited to Ankylosing Spondylitis, Psoriatic Arthritis, and Spondyloarthritis.

AiArthritis

The AiArthritis Research Database is part of the FORWARD Registry, and is launching in 2024 in collaboration with the patient advocacy group, AiArthritis (International Foundation for Autoimmune & Autoinflammatory Arthritis). This registry focuses on the roughly two dozen autoimmune and autoinflammatory arthritis disorders that affect 350 million people across the world.

FORWARD featured on “Health Uncensored with Dr. Drew.”

FORWARD is featured on Health Uncensored with Dr. Drew Dr. Drew Pinsky talks with FORWARD Director Kaleb Michaud, PhD about being a life-long patient with Rheumatoid Arthritis (RA), [...]

September 18th, 2024|

Research, Resilience, and JIA: Dr. Kaleb’s Journey

Dr. Kaleb Michaud speaks with Cheryl Crow on Episode 137 of the Arthritis Life podcast. Summary: Imagine being told at age 4 that you likely wouldn’t live past 21 due to [...]

September 17th, 2024|

Alira Health and FORWARD Launch Enhanced Lupus Patient Registry, Accelerating Solutions for Patients

Patients with Lupus share their health experiences within a secure registry to advance research, support better clinical decision-making, and improve patient outcomes. Read more about this in our joint press release [...]

November 6th, 2023|

Latest Publications

Information about recent research performed by FORWARD collaborators using FORWARD data.

Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID‐19 Pandemic

The authors of this study, which was led by Kaleb Michaud, Ph.D., of the University of Nebraska Medical Center in Omaha, and Kristin Wipfler, Ph.D., of FORWARD, set out to understand how the COVID-19 pandemic has impacted the lives of RA patients in the United States.

The impact of menopause on functional status in women with rheumatoid arthritis

The aim of this study was to investigate the association of menopause with functional status outcomes in women with RA.

The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis

To examine the comparative effects of biologic disease-modifying antirheumatic drugs and tofacitinib against conventional synthetic DMARDs on incident cardiovascular disease in patients with rheumatoid arthritis.

Read latest publications

“We take a long look at the outcomes of these illnesses. This allows us to conduct observational studies that tell us, for example, how well a drug works under real-life circumstances, unlike clinical trials, which tell you only how well a drug can work under idealized circumstances.”

Dr. Fred Wolfe, Founder

Home